Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | GLS | O94925 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6575878 | 0.96 | TDP1 (0.61) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL24468061 | 0.94 | TDP1 (0.64) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 | |
| SCHEMBL7259722 | 0.94 | TDP1 (0.64) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 | |
| SCHEMBL712860 | 0.94 | TDP1 (0.64) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 | |
| SCHEMBL1115054 | 0.89 | CES1 (0.63) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL6790333 | 0.89 | TDP1 (0.71) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4351612 | 0.89 | TDP1 (0.66) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3433208 | 0.87 | TDP1 (0.59) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL8862728 | 0.86 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 | |
| SCHEMBL2604742 | 0.86 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-12459945-B2 | Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents | Madera Therapeutics, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4612154-A1 | REGULATORS OF PORPHYRIN AND INTERMEDIATES | Madera Therapeutics, LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024097436-A1 | REGULATORS OF PORPHYRIN AND INTERMEDIATES | Madera Therapeutics, LLC (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| CN-112920065-B | Benzil compound and preparation method and application thereof | 上海中医药大学 | 2023-04-25 | — | — | CN | disclosed |
| US-20220089596-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2022-03-24 | — | — | US | disclosed |
| CN-113795251-A | Use of casein hydrolyzing protease P function as a biomarker of drug response to IMIPRIDONE-like agents | 马德拉治疗公司 | 2021-12-14 | — | — | CN | disclosed |
| WO-2003013526-A1 | ANTICOAGULANT COMPOUNDS | MERCK & CO. INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| US-20030013131-A1 | Immunoassay for LSD and 2-oxo-3-hydroxy-LSD | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6476199-B1 | Reagents for lysergic acid diethylamide immunoassay | ROCHE DIAGNOSTICS CORPORATION | 2002-11-05 | — | — | US | disclosed |
| US-20010044118-A1 | Immunoassay for LSD and 2-oxo-3-hydroxy-LSD | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2001-11-22 | — | — | US | disclosed |
| EP-1148339-A2 | Immunoassay for LSD and 2-Oxo-3-Hydroxy-LSD | Roche Diagnostics Corporation (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1123295-A1 | BICYCLIC NITROGEN HETEROCYCLES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-16 | — | — | EP | disclosed |
| US-6150373-A | AMINO-SUBSTITUTED DIHYDROPYRIMIDO(4,5-D)PYRIMIDINONE DERIVATIVES; INHIBITORS OF THE T-CELL TYROSINE KINASE P56LCK; IMMUNOSUPPRESSANTS; ANTIINFLAMMATORY/-CARCINOGENIC AGENTS; BRONCHOPULMONARY, DERMATOLOGICAL AND CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6063908-A | STABLE HAPTEN DERIVATIVES THAT ARE USEFUL FOR THE PREPARATION OF ANTIGENS, ANTIBODIES AND REAGENTS USED IN DETECTION OF DRUG ABUSE | ROCHE DIAGNOSTICS CORPORATION (US) | 2000-05-16 | — | — | US | disclosed |
| WO-2000024744-A1 | BICYCLIC NITROGEN HETEROCYCLES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-05-04 | — | — | WO | disclosed |
| EP-0816364-A1 | Reagents for lysergic acid diethylamide immunoassay | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044118-A1 | Immunoassay for LSD and 2-oxo-3-hydroxy-LSD | HNMT, HRH3, HRH4 | TDP1 2987/4885L3MBTL1 2194/4885MAPT 1944/4885 |
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CTRB1, CTRB2, CPN1 | TDP1 3079/4885L3MBTL1 2170/4885MAPT 4526/4885 |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CLPP, PRCP, PREP | TDP1 1210/4885L3MBTL1 2708/4885MAPT 1873/4885 |
| US-12459945-B2 | Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents | CLPP, PRCP, PREP | TDP1 1210/4885L3MBTL1 2708/4885MAPT 1873/4885 |
| US-20220089596-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | PRCP, PREP, TMPRSS15 | TDP1 828/4885L3MBTL1 4058/4885MAPT 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.